Tag Archives: variants

Coronavirus can transform pancreas cell function; certain genes may protect an infected person’s spouse

By Nancy Lapid

(Reuters) – The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review.

Coronavirus transforms pancreas cell function

When the coronavirus infects cells, it not only impairs their activity but can also change their function, new findings suggest. For example, when insulin-producing beta cells in the pancreas become infected with the virus, they not only produce much less insulin than usual, but also start to produce glucose and digestive enzymes, which is not their job, researchers found. “We call this a change of cell fate,” said study leader Dr. Shuibing Chen, who described the work in a presentation on Tuesday at the annual meeting of the European Association for the Study of Diabetes, held virtually this year. It is not clear whether the changes are long-lasting, or if they might be reversible, the researchers noted earlier in a report published in Cell Metabolism. Chen noted that some COVID-19 survivors have developed diabetes shortly after infection. “It is definitely worth investigating the rate of new-onset diabetes patients in this COVID-19 pandemic,” she said in a statement. Her team has been experimenting with the coronavirus in clusters of cells engineered to create mini-organs, or organoids, that resemble the lungs, liver, intestines, heart and nervous system. Their findings suggest loss of cell fate/function may be happening in lung tissues as well, Chen, from Weill Cornell Medicine in New York, told Reuters.

Certain genes may protect an infected patient’s spouse

A study of couples in which both partners were exposed to the coronavirus but only one person got infected is helping to shed light on why some people may be naturally resistant to the virus. The researchers had believed such cases were rare, but a call for volunteers who fit that profile turned up roughly a thousand couples. Ultimately, they took blood samples from 86 couples for detailed analysis. The results suggest resistant partners more often have genes that contribute to more efficient activation of so-called natural killer (NK) cells, which are part of the immune system’s initial response to germs. When NKs are correctly activated, they are able to recognize and destroy infected cells, preventing the disease from developing, the researchers explained in a report published on Tuesday in Frontiers in Immunology . “Our hypothesis is that the genomic variants most frequently found in the susceptible spouse lead to the production of molecules that inhibit activation of NKs,” study leader Mayana Zatz of the University of São Paulo, Brazil, said in a statement. The current study cannot prove this is happening, she added. Even if the findings are confirmed with more research, the contributions of other immune mechanisms would also need to be investigated, the researchers said.

Experimental pill shows promise against coronavirus variants

Laboratory studies show that Merck & Co’s experimental oral COVID-19 antiviral drug, molnupiravir, is likely to be effective in patients infected with any of the known variants of the coronavirus, including the dominant, highly transmissible Delta, researchers said on Wednesday in a presentation during IDWeek 2021, the virtual annual meeting of infectious disease organizations. Molnupiravir does not target the spike protein of the virus, which is the target of all current COVID-19 vaccines. Instead, it targets an enzyme the virus uses to make copies of itself. It is designed to work by introducing errors into the genetic code of the virus. Data showed that the drug is most effective when given early in the course of infection, Merck said. The company is conducting two large late-stage trials of the drug – one for treatment of COVID-19 and another as a preventive.

(Reporting by Nancy Lapid and Deena Beasley; Editing by Bill Berkrot)

Vaccines effective vs variants despite diminished antibodies; kids may be as contagious as adults

By Nancy Lapid

(Reuters) – The following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus.

Vaccines protect against variants despite diminished antibodies

The one-dose Johnson & Johnson COVID-19 vaccine and the two-dose vaccine from Pfizer and BioNTech appear to protect against worrisome coronavirus variants despite diminished levels of antibodies that can neutralize the newer versions of the virus, two studies in the journal Nature suggest. The authors of both studies said other immune responses may be compensating. In one study, published on Wednesday, researchers experimented with blood from people who had received the J&J vaccine two months earlier. Compared to their levels of neutralizing antibodies against the virus that was circulating early in the pandemic, levels of neutralizing antibodies against variants first identified in the UK, South Africa, Brazil and California were about three-fold lower. However, the researchers observed other “robust” immune activity and cells whose responses against the variants were undiminished. In clinical trials, the researchers noted, the J&J vaccine protected against symptomatic COVID-19 in South Africa and in Brazil, where most cases were caused by the variants. Its effectiveness in these regions raises the possibility that these other immune responses may be contributing to protection, coauthor Dr. Dan Barouch of Beth Israel-Deaconess Medical Center in Boston, said in a statement. In a separate study using blood from recipients of the Pfizer/BioNTech shots, levels of antibodies that could neutralize concerning variants first identified in India and Nigeria were lower compared to an earlier version of the virus, researchers reported on Thursday. Still, they reported “robust neutralization” of all tested variants. Neutralizing antibodies, the researchers said, do not reflect all potentially protective vaccine responses.

Children with COVID-19 may be as contagious as adults

In a community-based study of COVID-19 patients who were not hospitalized, U.S. researchers found that children and adults with symptoms had similar viral loads, which suggests children can be just as contagious as grownups. “There has been a lot of debate around school openings and about whether children could transmit the virus and we thought this study could help answer some of these questions,” said Dr. Helen Chu of the University of Washington, who coauthored a report published on Friday in JAMA Pediatrics. Her team looked at 123 children and 432 adults with COVID-19 and found that nearly all of the adults had symptoms, compared to about two-thirds of the children. “Overall, people with symptoms had higher virus levels than people without symptoms,” Chu said. “However, when you looked within these groups – those with symptoms or those without – viral load was the same whether you were a child or an adult.” She noted that swab tests were only done once, so researchers cannot be sure they took place when patients’ viral loads were highest. But overall, she said, children in the community with SARS-CoV-2 infection can have virus levels similar to adults and can transmit it to others.

Oral booster vaccine shows promise in animal tests

An experimental “booster” vaccine against COVID-19 that is taken by mouth has yielded promising early results in studies in rats, Israeli researchers said. The oral vaccine, MigVax-101, targets multiple sites on the coronavirus. Along with the spike protein on the surface of the virus, which is the target of currently available vaccines, the oral vaccine also targets two sites on the virus shell, which encapsulates its genetic material. In laboratory experiments, rats that had received two doses of vaccines that targeted the spike protein were given the oral booster. “These rats developed a much higher level of antibodies for neutralizing the disease than did control group rats that received a placebo or a third injection of the (original) vaccine,” said David Zigdon of MIGAL Galilee Research Institute Ltd, who coauthored a report posted on Wednesday on bioRxiv ahead of peer review. If it is proven safe for humans, an oral vaccine might trigger strong immune responses in the mucosal surfaces of the mouth and upper respiratory tract, which would in turn help block viral entry, the researchers speculated. An oral vaccine could be particularly useful in developing countries because it would avoid the need for distribution of needles and could be self-administered.

(Reporting by Nancy Lapid and Christine Soares; Editing by Bill Berkrot)

Exclusive: Regular booster vaccines are the future in battle with COVID-19 virus, top genome expert says

By Guy Faulconbridge

CAMBRIDGE, England (Reuters) – Regular booster vaccines against the novel coronavirus will be needed because of mutations that make it more transmissible and better able to evade human immunity, the head of Britain’s effort to sequence the virus’s genomes told Reuters.

The novel coronavirus, which has killed 2.65 million people globally since it emerged in China in late 2019, mutates around once every two weeks, slower than influenza or HIV, but enough to require tweaks to vaccines.

Sharon Peacock, who heads COVID-19 Genomics UK (COG-UK) which has sequenced nearly half of all the novel coronavirus genomes so far mapped globally, said international cooperation was needed in the “cat and mouse” battle with the virus.

“We have to appreciate that we were always going to have to have booster doses; immunity to coronavirus doesn’t last forever,” Peacock told Reuters at the non-profit Wellcome Sanger Institute’s 55-acre campus outside Cambridge.

“We already are tweaking the vaccines to deal with what the virus is doing in terms of evolution – so there are variants arising that have a combination of increased transmissibility and an ability to partially evade our immune response,” she said.

Peacock said she was confident regular booster shots – such as for influenza – would be needed to deal with future variants but that the speed of vaccine innovation meant those shots could be developed at pace and rolled out to the population.

COG-UK was set up by Peacock, a professor at Cambridge, exactly a year ago with the help of the British’s government’s chief scientific adviser, Patrick Vallance, as the virus spread across the globe to Britain.

The consortium of public health and academic institutions is now the world’s deepest pool of knowledge about the virus’s genetics: At sites across Britain, it has sequenced 349,205 genomes of the virus out of a global effort of around 778,000 genomes.

On the intellectual frontline at the Wellcome Sanger Institute, hundreds of scientists – many with PhDs, many working on a voluntary basis and some listening to heavy metal or electronic beats – work seven days a week to map the virus’s growing family tree for patterns of concern.

Wellcome Sanger Institute has sequenced over half of the UK total sequenced genomes of the virus after processing 19 million samples from PCR tests in a year. COG-UK is sequencing around 30,000 genomes per week – more than the UK used to do in a year.

MUTATION LEADERBOARD

Three main coronavirus variants – which were first identified in Britain (known as B.1.1.7), Brazil (known as P1) and South Africa (known as B.1.351) – are under particular scrutiny.

Peacock said she was most worried about B.1.351.

“It is more transmissible, but it also has a change in a gene mutation, which we refer to as E484K, which is associated with reduced immunity – so our immunity is reduced against that virus,” Peacock said.

With 120 million cases of COVID-19 around the world, it is getting hard to keep track of all the alphabet soup of variants, so Peacock’s teams are thinking in terms of “constellations of mutations”.

“So a constellation of mutations would be like a leaderboard if you like – which mutations in the genome that we’re particularly concerned about, the E484K is must be one of the top of the leaderboard,” she said.

“So we’re developing our thinking around that leaderboard to think, regardless of the background and lineage, about what mutations or constellation of mutations are going to be important biologically and different combinations that may have slightly different biological effects.”

Peacock, though, warned of humility in the face of a virus that has brought so much death and economic destruction.

“One of the things that the virus has taught me is that I can be wrong quite regularly – I have to be quite humble in the face of a virus that we know very little about still,” she said.

“There may be a variant out there that we haven’t even discovered yet.”

There will, though, be future pandemics.

“I think its inevitable that we will have another virus emerge that is of concern. What I hope is that having learned what we have in this global pandemic, that we will be better prepared to detect it and contain it.”

(Reporting by Guy Faulconbridge; Editing by Kate Holton and Philippa Fletcher)

Trials of retooled vaccines for variants could take months: U.S. FDA

By Michael Erman

(Reuters) – Drugmakers should test any COVID-19 vaccines that have been retooled to combat new variants of the coronavirus in clinical trials designed to track the immune response of hundreds of test subjects, which could take months, U.S. regulators said on Monday.

Vaccine developers may need to modify their shots to provide protection against new variants of the coronavirus that turn up in the United States should they fail to elicit immune response in their current form, the U.S. Food and Drug Administration said in a statement.

The FDA said it believes currently authorized vaccines from Pfizer Inc with partner BioNTech SE and Moderna Inc. are effective against variants currently circulating in the United States.

Acting FDA Commissioner Janet Woodcock said drugmakers should not wait until a mutated virus is demonstrated to be able to escape the vaccines to begin developing new versions.

“We need to anticipate this and work on it, so that we have something in our back pocket before the threshold is upon us,” she said at a news conference.

The emergence of new, more contagious variants has prompted the U.S. government to step up efforts to track coronavirus mutations and try to keep vaccines and treatments effective against any new variants.

Pfizer and Moderna have both said they plan to run clinical trials of versions of their vaccine that have been redesigned to combat the highly contagious COVID-19 variant that has become prevalent South Africa and has turned up in several U.S. States.

The FDA made the comments as part of a newly updated guidance for companies making vaccines, tests and therapeutics for COVID-19.

As part of its updated guidance, the FDA recommended that vaccine makers test any modified vaccines in both previously unvaccinated people and vaccinated people. The manufacturers should compare the immune response of a modified vaccine against both the new variant as well as the original virus.

The FDA also recommended monitoring test subjects’ safety for at least seven days, to support emergency use authorization for modified vaccines.

The agency is trying to allow drugmakers to make the change with a minimal amount of extra data needed, said Dr. Peter Marks, director of the FDA’s Center for Biologics Evaluation and Research.

Still, the type of trial the agency wants, “might take a few months, whether it be two or three,” Marks said. “I can’t say exactly how long but again, that type of the scale of the amount of time.”

“We want to be ready so that we can move it into production, when it’s ready and when it’s needed,” he said.

(Additional reporting by Manojna Maddipatla and Mrinalika Roy in Bengaluru; Editing by Jonathan Oatis and Bill Berkrot)

J&J adds to COVID-19 vaccine armory with 66% efficacy in global trial

By Julie Steenhuysen

(Reuters) – Johnson & Johnson said on Friday that its single-dose vaccine was 66% effective in preventing COVID-19 in a large global trial against multiple variants which will give health officials another weapon to tackle the coronavirus.

In the trial of nearly 44,000 volunteers, the level of protection against moderate and severe COVID-19 varied from 72% in the United States, to 66% in Latin America and just 57% in South Africa, from where a worrying variant has spread.

A high bar has been set by two authorized vaccines from Pfizer/BioNTech and Moderna, which were around 95% effective in preventing symptomatic illness in pivotal trials when given in two doses.

Those trials, however, were conducted mainly in the United States and before new variants emerged.

The top U.S. infectious disease specialist Anthony Fauci said the variations in effectiveness around the world underlined the need to vaccinate as many people as quickly as possible to prevent new variants from emerging.

“It’s really a wake up call for us to be nimble and to be able to adjust as this virus will continue for certain to evolve,” Fauci said.

J&J’s main goal was the prevention of moderate to severe COVID-19, and the vaccine was 85% effective in stopping severe disease and preventing hospitalization across all geographies and against multiple variants 28 days after immunization.

That “will potentially protect hundreds of millions of people from serious and fatal outcomes of COVID-19,” Paul Stoffels, J&J’s chief scientific officer, said of the results, which were based on 468 symptomatic cases.

SEEKING APPROVAL

J&J plans to seek emergency use authorization from the U.S. Food and Drug Administration next week. It has said it plans to deliver 1 billion doses in 2021 and will produce the vaccine in the United States, Europe, South Africa and India.

Public health officials are counting on the J&J vaccine to increase much-needed supply and simplify immunization in the United States, which has a deal to buy 100 million doses of J&J’s vaccine and an option for an additional 200 million.

J&J said the vaccine would be ready immediately upon emergency approval, but Stoffels declined to say how many doses.

“Right now, any protection and additional vaccine is great. The key is not only overall efficacy but specifically efficacy against severe disease, hospitalization, and death,” Walid Gellad, a health policy associate professor at the University of Pittsburgh, said.

Michael Breen, Director of Infectious Diseases and Ophthalmology at research firm GlobalData said “Most countries are still desperate to get their hands on doses, regardless of whether or not the vaccine is considered highly effective. Moderately effective will do just fine for now.”

None of the vaccine recipients in the J&J trial died from COVID-19, compared with 5 in the placebo group, the National Institutes of Health said. Three deaths in the vaccine group overall, but none were determined to be from the virus. That compares with 16 deaths overall in the placebo arm, it added.

Unlike the Pfizer and Moderna vaccines, J&J’s does not require a second shot weeks after the first or need to be kept frozen, making it a strong candidate for use in parts of the world where transportation and cold storage are an issue.

SOUTH AFRICAN VARIANT

Several studies have emerged this month showing that a South African variant has mutated in areas of the virus that are key targets of vaccines, reducing their efficacy.

“What we are learning is there is different efficacy in different parts of the world,” Stoffels told Reuters.

In a sub-study of 6,000 volunteers in South Africa, Stoffels said, the J&J vaccine was 89% effective at preventing severe disease. In the South Africa portion of the trial, 95% of cases were infections with the South African variant.

“I am overwhelmed by the fact that this vaccine protected against severe disease even in South Africa,” said Glenda Gray, the joint lead investigator of the South African vaccine trial.

Gray, who is the chief executive of the South African Medical Research Council, said this is by far the best vaccine for South Africa to fight the mutant strain and can prevent a large number of hospitalizations and deaths.

A mid-stage trial of a Novovax coronavirus vaccine in South Africa also showed lower efficacy, proving to be 60% effective among volunteers who didn’t have HIV. In a separate, late-stage trial in Britain it was 89.3% effective.

In the J&J trial, which was conducted in eight countries, 44% of participants were from the United States, 41% from Central and South America and 15% from South Africa. Slightly more than a third of the volunteers were over 60.

J&J’s vaccine uses a common cold virus to introduce coronavirus proteins into cells in the body and trigger an immune response, whereas the Pfizer/BioNTech and Moderna vaccines use a new technology called messenger RNA (mRNA).

(Reporting by Julie Steenhuysen; Additional reporting by Manas Mishra, Dania Nadeem and Manojna Maddipatla in Bengalaru and Rebecca Spalding and Michael Erman in New York; Writing by Alexander Smith; Editing by Caroline Humer, Peter Henderson, Edwina Gibbs and Keith Weir)

Racing the virus: Why tweaking the vaccines won’t be simple

By Julie Steenhuysen and Michael Erman

CHICAGO (Reuters) – After developing and rolling out COVID-19 vaccines at record speed, drugmakers are already facing variants of the rapidly-evolving coronavirus that may render them ineffective, a challenge that will require months of research and a massive financial investment, according to disease experts.

Executives from Moderna Inc and Pfizer Inc and partner BioNTech SE are considering new versions of their vaccines to respond to the most concerning variants identified so far. That is just one piece of the work needed to stay ahead of the virus, nearly a dozen experts told Reuters.

A global surveillance network to assess emerging variants must be built. Scientists need to establish what level of antibodies will be required to protect people from COVID-19 and determine when vaccines need to be altered. And regulators must convey what is needed to demonstrate updated vaccines are still safe and effective.

“At this point, there is no evidence that these variants have changed the equation in terms of protection from the vaccine,” said Dr. Michael Osterholm, an infectious disease expert at the University of Minnesota. “But we have to be prepared for that.”

Johnson & Johnson told Reuters the concerning variant first identified in South African has got its attention and will tweak its vaccine accordingly if needed. Pfizer said it could produce a new vaccine relatively quickly, but a top vaccine executive said manufacturing it presents additional challenges.

The urgency of this effort is clear.

Moderna on Monday said lab studies showed antibodies made in response to its vaccine were six times less effective at neutralizing a lab-created version of a South African variant than prior versions of the virus.

A study released on Wednesday ahead of peer review found the South African variant reduced neutralizing antibodies 8.6-fold for the Moderna vaccine and by 6.5-fold for the Pfizer/BioNTech shot, although a separate Pfizer-backed study released on Wednesday suggests its vaccine may be more hardy. Moderna said this week it is starting work on a potential booster shot.

COULD TAKE MONTHS

Just how far protection can drop before a COVID-19 vaccine needs to be altered is not yet known. With influenza, an eightfold drop in vaccine-induced antibody protection means time to update. That does not necessarily apply to this coronavirus.

“The problem is we don’t know what the cut point is for coronavirus,” said Dr. John Mascola, director of the Vaccine Research Center at the National Institute of Allergy and Infectious Diseases (NIAID), whose scientists helped develop Moderna’s vaccine.

Mascola said both studies testing the Moderna vaccine against the South African variant are roughly in the “same ballpark.” It could be that antibody protection is high enough from the vaccine that it will still be effective, he said.

NIAID scientists are analyzing data from Moderna’s late-stage trial to see what level of neutralizing antibodies is required for protection. They are comparing individuals who were vaccinated but got sick anyway to vaccinated people who remained healthy.

It could take two months to complete this work, Mascola said. They hope to produce a benchmark for the minimum level of vaccine-induced antibodies needed to protect against COVID-19.

A global surveillance network is also needed to identify troubling new variants as they emerge, similar to one used to track fast-mutating flu viruses. That could cost tens to hundreds of millions of dollars in the United States alone.

Richard Webby, a flu surveillance expert from St. Jude Children’s Research Hospital, said the United States could probably build a system to identify variants fairly quickly. Developing the capability to determine whether they evade current vaccines will take more time.

The United States is currently conducting genetic sequencing to look for changes in the virus in just 0.3% of positive coronavirus tests. That pales compared with 10% in the UK, which was first to discover a major mutation in the virus that increases transmission by at least 50%. Experts said countries should sequence at least 5% of positive cases to detect significant changes in the virus.

Companies are waiting for the U.S. Food and Drug Administration to relay what testing will be needed for altered vaccines, said Phil Dormitzer, one of Pfizer’s top viral vaccine scientists. With influenza vaccines, companies can make changes without new trials. “But that’s after doing it for 50 years,” he said.

Peter Marks, who oversees the FDA’s vaccine approval process, has said small trials testing updated vaccines in around 400 participants may be needed at first. Even that could add months to the process.

Norman Baylor, chief executive of Biologics Consulting and a former FDA vaccines official, said the agency will lay out the regulatory road. But public health agencies like the U.S. Centers for Disease Control and Prevention and the World Health Organization would decide when vaccines should be updated, as with flu.

Altering Pfizer’s vaccine would require “a very minor change,” Dormitzer said.

Like Moderna’s, it uses messenger RNA (mRNA) technology, which relies on synthetic genes that can be generated and manufactured in weeks.

He estimates the company could make a prototype version in a week or so, and take another two months to scale up and update their lab tests.

J&J, which is expected to release late-stage trial data on its vaccine within days, has laid the groundwork to address troubling virus changes, Chief Scientific Officer Paul Stoffels told Reuters. Its trial included sites in South Africa, which should give the company insight on that variant.

If a change is necessary, Stoffels said J&J likely would add a second strain into its existing vaccine.

“We are looking at this with a lot of attention,” he said.

(Reporting by Julie Steenhuysen in Chicago and Michael Erman in New York; Editing by Caroline Humer and Bill Berkrot)

UK plans tough new border measures to combat coronavirus

By William James and Michael Holden

LONDON (Reuters) – Britain will announce new tougher border measures on Wednesday to stop new variants of COVID-19 getting into the country, Prime Minister Boris Johnson said as he promised to deliver a roadmap out of lockdowns that have shuttered much of the economy.

The government is expected to bring in quarantine hotels for those coming to Britain from high-risk countries where new strains of the coronavirus have emerged – so-called red list nations – such as South Africa and those in South America.

The move comes as Britain’s death toll from COVID-19 surpassed 100,000, the first European state to reach that figure, leading to further questions about Johnson’s handling of the crisis.

“The Home Secretary (interior minister) will be setting out later today…even tougher measures for those red list countries where we are particularly concerned about new variants,” Johnson told parliament when asked about plans to strengthen Britain’s borders.

Britain saw infections soar at the end of last year after a highly-contagious new variant that emerged in southeast England surged through the population, taking cases and later deaths to record levels.

Since the start of January, all the United Kingdom has faced lockdowns which have closed schools, pubs and restaurants to all bar takeaways with the public told they must stay home as much as possible.

Johnson and his ministers have faced repeated questions, including from many in his own party, on when measures would be eased especially with regard to school closures. He told lawmakers he would address that issue later on Wednesday when he is due to host a media conference.

“Then in the course of the next few weeks, assuming the vaccine rollout continues well, assuming we don’t find new variants of concern…I will be setting out a broader roadmap for the way forward for the whole country,” he said.

With 100,162 recorded deaths, Britain has the world’s fifth highest toll from COVID-19 and the highest deaths per 100,000 people in the world.

Johnson said he felt deep sorrow about the loss of life when the figures were announced on Tuesday, but said the government had done everything it could.

Asked repeatedly by the leader of the Labor opposition Keir Starmer why Britain had fared so badly, he said there would be a time to learn the lessons of what happened but “I don’t think that moment is now” when 37,000 people were still in hospital suffering from the virus.

“There are no easy answers, perpetual lockdown is no answer,” he said.

(Additional reporting by Elizabeth Piper; Editing by Angus MacSwan)

Global COVID-19 cases surpass 100 million as nations tackle vaccine shortages

By Shaina Ahluwalia and Roshan Abraham

(Reuters) – Global coronavirus cases surpassed 100 million on Wednesday, according to a Reuters tally, as countries around the world struggle with new virus variants and vaccine shortfalls.

Almost 1.3% of the world’s population has now been infected with COVID-19, the disease caused by the novel coronavirus, and more than 2.1 million people have died.

One person has been infected every 7.7 seconds, on average, since the start of the year. Around 668,250 cases have been reported each day over the same period, and the global fatality rate stands at 2.15%.

The worst-affected countries – the United States, India, Brazil, Russia and the United Kingdom – make up more than half all reported COVID-19 cases but represent 28% of the global population, according to a Reuters analysis.

It took the world 11 months to record the first 50 million cases of the pandemic, compared to just three months for cases to double to 100 million.

Around 56 countries have begun vaccinating people for the coronavirus, administering at least 64 million doses. Israel leads the world on per capita vaccinations, inoculating 29% of its population with at least one dose.

UNITED STATES

With over 25 million cases, the United States has 25% of all reported COVID cases although it accounts for just 4% of the world’s population. The United States leads the world in the daily average number of new deaths reported, accounting for one in every five deaths reported worldwide each day. With just under 425,00 fatalities, the United States has reported almost twice as many deaths as Brazil, which has the second-highest death toll in the world.

As the worst-affected region in the world, Europe is currently reporting a million new infections about every four days and has reported nearly 30 million since the pandemic began. Britain on Tuesday reached 100,000 deaths.

The Eastern European region, including countries like Russia, Poland and Ukraine, contribute to nearly 10% of all global COVID-19 cases.

Despite securing deals for vaccine supplies early on, many European countries are facing delays in shipments from both Pfizer Inc and AstraZeneca Plc.

ASIA AND AFRICA

In India, the nation with the second-highest number of cases, infections are decreasing, with almost 13,700 new infections reported on average each day – around 15% of its peak. Prime Minister Narendra Modi said on Friday India was completely self-reliant on coronavirus vaccine supplies as the world’s second-most populous country inoculated more than 1 million people within a week of starting its campaign.

China, which recently marked the first anniversary of the world’s first coronavirus lockdown in the central city of Wuhan, is facing its worst wave of local cases since March last year.

As richer nations race ahead with mass vaccination campaigns, Africa is still scrambling to secure supplies as it grapples with concerns about more-infectious variants of the virus first identified in South Africa and Britain.

According to the Reuters tally, African countries have nearly 3.5 million cases and over 85,000 deaths.

The South African variant, also known as 501Y.V2, is 50% more infectious and has been detected in at least 20 countries.

U.S. President Joe Biden will impose a ban on most non-U.S. citizens entering the country who have recently been in South Africa starting Saturday in a bid to contain the spread of a new variant of COVID-19.

Australia and New Zealand have fared better than most other developed economies during the pandemic through swift border closures, lockdowns, strict hotel quarantine for travelers and widespread testing and social distancing.

“We have the virus under control here in Australia, but we want to roll out the vaccine,” Australian Treasurer Josh Frydenberg told a news conference on Sunday.

(Reporting by Shaina Ahluwalia and Roshan Abraham in Bengaluru; Editing by Lisa Shumaker and Jane Wardell)

UK surpasses 100,000 COVID deaths in grim new milestone

LONDON (Reuters) – More than 100,000 Britons have died within 28 days of a positive COVID-19 test, official data showed on Tuesday, a grim new milestone as the government battles to speed up vaccination delivery and keep variants of the virus at bay.

Britain has the fifth highest toll globally and reported a further 1,631 deaths and 20,089 cases on Tuesday, according to government figures.

The 100,162 deaths are more than the country’s civilian toll in World War Two and twice the number killed in the 1940-41 Blitz bombing campaign, although the total population was lower then.

“My thoughts are with each and every person who has lost a loved one – behind these heart-breaking figures are friends, families and neighbors,” health minister Matt Hancock said.

“I know how hard the last year has been, but I also know how strong the British public’s determination is and how much we have all pulled together to get through this.”

England, by far the most populous of the UK’s four nations, re-entered a national lockdown on Jan. 5, which includes the closure of pubs, restaurants, non-essential shops and schools to most pupils. Further travel restrictions have been introduced.

In December, Britain became the first country in the world to approve Pfizer’s COVID-19 vaccine and has set itself the task of offering jabs to everyone 70 and over, those who are clinically vulnerable, frontline health and social care workers and older adults in care homes by mid-February.

A total of 6,853,327 people have now received a first dose and 472,446 a second dose.

(Reporting by Costas Pitas; editing by Michael Holden)

White House confirms Biden signing new South Africa travel restrictions

WASHINGTON (Reuters) – The White House confirmed President Joe Biden is signing an order on Monday imposing a ban on most non-U.S. citizens entering the country who have recently been in South Africa starting Saturday.

White House spokeswoman Jen Psaki also confirmed Biden will re-impose an entry ban on nearly all non-U.S. travelers who have been in Brazil, the United Kingdom, Ireland and 26 countries in Europe that allow travel across open borders that was set to expire Tuesday.

“With the pandemic worsening and more contagious variants spreading, this isn’t the time to be lifting restrictions on international travel,” Psaki said at a news briefing.

(Reporting by David Shepardson; Editing by Chris Reese)